The tumor is removed and the site frozen with liquid nitrogen (cryosurgery) to
kill any remaining tumor cells.
The idea: trigger immune activity within the brain itself to
kill remaining tumor cells — the ones neurosurgeons can't take out, which make this type of tumor so dangerous.
Not exact matches
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not
kill all of the
tumor cells, and the
remaining cells adapt to treatment and become resistant.
If a given drug cocktail
kills 90 percent of the cancer
cells but doesn't affect the
remaining 10 percent, the resistant
tumor cells can take over and cause the
tumor to grow back.
They find that the
cells can
remain dormant during chemotherapy that
kills off most of the cancer and can give rise to new
tumors once the drug treatment stops.
The vaccine is unique to the individual participant and is engineered to trigger an immune system response to
kill tumor cells that may
remain following surgery.
Technology such as this, scientists said, may have a promising future in the identification and surgical removal of malignant
tumors, as well as using near - infrared light therapies that can
kill remaining cancer
cells, both by mild heating of them and generating reactive oxygen species that can also
kill them.
Researchers at Oregon State University have developed a new way to selectively insert compounds into cancer
cells — a system that will help surgeons identify malignant tissues and then, in combination with phototherapy,
kill any
remaining cancer
cells after a
tumor is removed.
In any of these forms, drugs are administered to
kill remaining cancer
cells after removing a
tumor in surgery (adjuvant), shrink an existing
tumor prior to surgery (neoadjuvant), or quicken remission for specific blood - borne cancers (induction).
It may be used before surgery to shrink very large
tumors, or after surgery to
kill cancer
cells that may have
remained.